Literature DB >> 17287647

Quantitative measurements of perfusion and permeability of oropharyngeal and oral cavity cancer, recurrent disease, and associated lymph nodes using first-pass contrast-enhanced computed tomography studies.

Sotirios Bisdas1, Mehran Baghi, Agnieszka Smolarz, Nicole Chambron Pihno, Thomas Lehnert, Rainald Knecht, Martin G Mack, Thomas J Vogl, Sehib Tuerkay, Tong San Koh.   

Abstract

OBJECTIVES: We sought to evaluate the routine clinical use of perfusion computed tomography in the detection and differentiation of primary and recurrent oropharynx and oral cavity tumors as well as of nodal disease.
MATERIALS AND METHODS: A total of 77 patients with primary cancer as well as suspected recurrent disease and lymph nodes were evaluated. A dynamic acquisition (4 x 6-mm slices) of the largest axial tumor surface was performed and the tumor blood flow (BF), blood volume (BV), and mean transit time (MTT) were calculated by using a modified deconvolution-based analysis taking into account the extravasation of the contrast agent for permeability surface area product imaging (PS). Tumor volume was calculated and region of interest analysis was performed on the pathologic and normal tissue.
RESULTS: The mean BF, BV, and PS values in the primary tumors (77.48 mL/min/100 g tissue; 5.29 mL/min; 13.33 mL/min/100 g tissue, respectively) were highly significantly different (P < 0.01) than those obtained in the normal structures. Mean MTT values (9.01 seconds) also were significantly lowered in the tumors compared with normal tissue (P < 0.05). There was no statistical difference in the perfusion values between the primary and the recurrent tumors. Recurrent disease could be differentiated on the basis of BF (P < 0.05) from tissue changes after chemo-radiation-treatment (mean BF: 69.71 versus 45.31 mL/min/100 g tissue, respectively). Differentiation of the lymph nodes was not possible by means of perfusion values. Tumor volume did not significantly correlate with any perfusion parameter.
CONCLUSIONS: Perfusion CT of oropharyngeal and oral cavity cancer in clinical routine is feasible and helps outlining the malignant tissue as well as differentiating recurrent disease from nonspecific post-therapeutic changes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287647     DOI: 10.1097/01.rli.0000252496.74242.0b

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  27 in total

Review 1.  Biologic imaging of head and neck cancer: the present and the future.

Authors:  A Srinivasan; S Mohan; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-22       Impact factor: 3.825

Review 2.  Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements.

Authors:  Gunnar Brix; Jürgen Griebel; Fabian Kiessling; Frederik Wenz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

Review 3.  Squamous cell carcinoma of the head and neck-The role of diffusion and perfusion imaging in tumor recurrence and follow-up.

Authors:  Agnieszka Trojanowska
Journal:  Rep Pract Oncol Radiother       Date:  2011-07-19

Review 4.  Functional magnetic resonance imaging of head and neck cancer: Performance and potential.

Authors:  Ahmed H El Beltagi; Ahmed H Elsotouhy; Ahmed M Own; Wael Abdelfattah; Kavitha Nair; Surjith Vattoth
Journal:  Neuroradiol J       Date:  2018-11-06

5.  An exploratory pilot study into the association between microcirculatory parameters derived by MRI-based pharmacokinetic analysis and glucose utilization estimated by PET-CT imaging in head and neck cancer.

Authors:  Sotirios Bisdas; Oliver Seitz; Markus Middendorp; Nicole Chambron-Pinho; Theodosios Bisdas; Thomas J Vogl; Renate Hammerstingl; Ulrike Ernemann; Martin G Mack
Journal:  Eur Radiol       Date:  2010-05-05       Impact factor: 5.315

6.  Optimization of perfusion CT protocol for imaging of extracranial head and neck tumors.

Authors:  Sotirios Bisdas; Chuan Zhi Foo; Choon Hua Thng; Thomas J Vogl; Tong San Koh
Journal:  J Digit Imaging       Date:  2008-05-03       Impact factor: 4.056

Review 7.  CT perfusion in oncology: how to do it.

Authors:  G Petralia; L Bonello; S Viotti; L Preda; G d'Andrea; M Bellomi
Journal:  Cancer Imaging       Date:  2010-02-11       Impact factor: 3.909

Review 8.  Cancer of the oral cavity and oropharynx.

Authors:  Dechen Wangmo Tshering Vogel; Peter Zbaeren; Harriet C Thoeny
Journal:  Cancer Imaging       Date:  2010-03-16       Impact factor: 3.909

9.  Human papillomavirus, p16, and epidermal growth factor receptor biomarkers and CT perfusion values in head and neck squamous cell carcinoma.

Authors:  N L Hoefling; J B McHugh; E Light; B Kumar; H Walline; M Prince; C Bradford; T E Carey; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2013-01-31       Impact factor: 3.825

10.  Perfusion CT in squamous cell carcinoma of the upper aerodigestive tract: long-term predictive value of baseline perfusion CT measurements.

Authors:  S Bisdas; Z Rumboldt; K Surlan-Popovic; M Baghi; T S Koh; T J Vogl; M G Mack
Journal:  AJNR Am J Neuroradiol       Date:  2009-10-29       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.